Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF
Status:
Completed
Trial end date:
2019-06-03
Target enrollment:
Participant gender:
Summary
This is a 24 week open label study to assess the efficacy of bi-weekly ranibizumab for
patients with retinal fluid due to exudative macular degeneration refractory to monthly
therapy.